← Back to Search

Diagnostic Test

Diagnostic algorithm for Heparin Induced Thrombocytopenia (HIT Trial)

N/A
Waitlist Available
Led By Lisa Duffett, MSc, MD
Research Sponsored by Ottawa Hospital Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patient with clinical suspicion of HIT by treating physician
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

HIT Trial Summary

This trial is testing a new method for diagnosing HIT, which is a blood clotting disorder.

Eligible Conditions
  • Heparin Induced Thrombocytopenia

HIT Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

HIT Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
False negative management failures
Recruitment
Secondary outcome measures
Death
Major arterial and venous thromboembolism events
Myocardial infarction
+4 more

HIT Trial Design

1Treatment groups
Experimental Treatment
Group I: diagnostic algorithmExperimental Treatment1 Intervention
Optimizing the interpretation of the more readily available anti-PF4 assay would reduce the reliance on functional testing/ confirmatory testing (Serotonin Release Assay, SRA) and the number of patients exposed to unnecessary changes in anticoagulation therapy while awaiting the timely functional test results

Find a Location

Who is running the clinical trial?

Ottawa Hospital Research InstituteLead Sponsor
561 Previous Clinical Trials
2,785,511 Total Patients Enrolled
Lisa Duffett, MSc, MDPrincipal InvestigatorOttawa Hospital Research Institute

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Journal of Thrombosis and HaemostasisJournal
Definition of Major Bleeding in Clinical Investigations of Antihemostatic Medicinal Products in Non-surgical Patients
SCHULMAN, S., C. KEARON, and the SUBCOMMITTEE ON CONTROL OF ANTICOAGULATION OF THE SCIENTIFIC AND STANDARDIZATION COMMITTEE OF THE INTERNATIONAL SOCIETY ON THROMBOSIS AND HAEMOSTASIS. 2005. “Definition of Major Bleeding in Clinical Investigations of Antihemostatic Medicinal Products in Non-surgical Patients”. Journal of Thrombosis and Haemostasis. Wiley. doi:10.1111/j.1538-7836.2005.01204.x.
American Journal of HematologyJournal
What Is the Potential for Overdiagnosis of Heparin-induced Thrombocytopenia?
Lo, Gregory K., Christopher S. Sigouin, and Theodore E. Warkentin. 2007. “What Is the Potential for Overdiagnosis of Heparin-induced Thrombocytopenia?”. American Journal of Hematology. Wiley. doi:10.1002/ajh.21032.
Journal of Thrombosis and HaemostasisJournal
Laboratory Testing for Heparin-induced Thrombocytopenia: A Conceptual Framework and Implications for Diagnosis
WARKENTIN, T. E., A. GREINACHER, Y. GRUEL, R. H. ASTER, B. H. CHONG, and on behalf of the scientific and standardization committee of the international society on thrombosis and haemostasis. 2011. “Laboratory Testing for Heparin-induced Thrombocytopenia: A Conceptual Framework and Implications for Diagnosis”. Journal of Thrombosis and Haemostasis. Wiley. doi:10.1111/j.1538-7836.2011.04536.x.
Journal of Thrombosis and HaemostasisJournal
Heparin-induced Thrombocytopenia: Towards Standardization of Platelet Factor 4/heparin Antigen Tests
GREINACHER, A., T. ITTERMANN, J. BAGEMÜHL, K. ALTHAUS, B. FÜRLL, S. SELLENG, N. LUBENOW, S. SCHELLONG, J. I. SHEPPARD, and T.E. WARKENTIN. 2010. “Heparin-induced Thrombocytopenia: Towards Standardization of Platelet Factor 4/heparin Antigen Tests”. Journal of Thrombosis and Haemostasis. Wiley. doi:10.1111/j.1538-7836.2010.03974.x.
All > Thrombocytopenia
~28 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top